Generation Of a Lung Biobank for Future Use — GOLF  

Cancer Clinical Trial

Official title: Generation Of a Lung Biobank for Future Use

Status Recruiting

Clinical Trial Summary

The aim is to invite 1,000 patients with symptoms triggering the lung cancer diagnostic pathway or with significant risks of lung cancer, referred to The Royal Marsden NHS Foundation Trust (RMH) referral centres (Kingston Hospital NHS Foundation Trust, Epsom and St Helier University Hospitals NHS Trust, Croydon University Hospitals NHS Foundation Trust or St George's University Hospitals NHS Foundation Trust) over a 1 year period, to complete a life style questionnaire, document lung function tests and to donate a blood sample for storage with a view to testing for a genetic signature and other biomarkers in future studies from this established biobank.

Clinical Trial Description

Patients will have been referred under the two week rule (TWR) diagnostic pathway, some will have lung cancer, others not, and other patients will have had a diagnosis of lung cancer by other pathways i.e. non TWR. There are 3 groups of patients: Group A - lung cancer patients at any stage and by any non TWR pathway, n=250. Group B - lung cancer patients who were referred initially by the TWR pathway, n=150. Group C - Subjects referred by the TWR pathway (i.e. with symptoms) who do not have lung cancer, or subjects referred by any pathway who do not have lung cancer but do have radiological changes (that need follow up) or a strong family history of lung cancer, n=600. A strong family history for this study means 1 or more first degree relatives with lung cancer with at least one individual having lung cancer at age <50 yrs. ;

Related Conditions & MeSH terms

• Cancer
• Lung Cancer

• NCT number: NCT05234138
• Study type: Observational
• Source: Royal Marsden NHS Foundation Trust
• Contact: Mary O'Brien
• Phone: 020 8642 6011
• Email: Lung.Trials@rmh.nhs.uk
• Status: Recruiting
• Start date: October 31, 2019
• Completion date: October 31, 2023